HUP9701695A3 - Use of 5-ethoxycarbonyl-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate of 2-[n-(1,2-benzisothiazolyl-3(2h)one-1,1-dioxide]ethyl for producing pharmaceuticals against atherosclerosis - Google Patents

Use of 5-ethoxycarbonyl-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate of 2-[n-(1,2-benzisothiazolyl-3(2h)one-1,1-dioxide]ethyl for producing pharmaceuticals against atherosclerosis

Info

Publication number
HUP9701695A3
HUP9701695A3 HU9701695A HUP9701695A HUP9701695A3 HU P9701695 A3 HUP9701695 A3 HU P9701695A3 HU 9701695 A HU9701695 A HU 9701695A HU P9701695 A HUP9701695 A HU P9701695A HU P9701695 A3 HUP9701695 A3 HU P9701695A3
Authority
HU
Hungary
Prior art keywords
benzisothiazolyl
dihydropyridine
ethoxycarbonyl
carboxylate
trimethyl
Prior art date
Application number
HU9701695A
Other languages
English (en)
Original Assignee
Alter Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alter Lab filed Critical Alter Lab
Publication of HUP9701695A2 publication Critical patent/HUP9701695A2/hu
Publication of HUP9701695A3 publication Critical patent/HUP9701695A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HU9701695A 1995-08-25 1996-08-20 Use of 5-ethoxycarbonyl-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate of 2-[n-(1,2-benzisothiazolyl-3(2h)one-1,1-dioxide]ethyl for producing pharmaceuticals against atherosclerosis HUP9701695A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95500122A EP0771560A1 (en) 1995-08-25 1995-08-25 Use of 2- N-(1,2-benzoisothiazolyl-3(2H)one-1,1-dioxide ethyl 5-ethoxycarbonyl-2,4,6-trimethyl-1,4-dihydropiridine-3-carboxylate in the treatment of vascular disorders

Publications (2)

Publication Number Publication Date
HUP9701695A2 HUP9701695A2 (hu) 1998-03-30
HUP9701695A3 true HUP9701695A3 (en) 1999-10-28

Family

ID=8221657

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9701695A HUP9701695A3 (en) 1995-08-25 1996-08-20 Use of 5-ethoxycarbonyl-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate of 2-[n-(1,2-benzisothiazolyl-3(2h)one-1,1-dioxide]ethyl for producing pharmaceuticals against atherosclerosis

Country Status (12)

Country Link
EP (1) EP0771560A1 (hu)
JP (1) JPH10508879A (hu)
KR (1) KR970706817A (hu)
AU (1) AU6931496A (hu)
BR (1) BR9606691A (hu)
CA (1) CA2203624A1 (hu)
EA (1) EA199700053A1 (hu)
HU (1) HUP9701695A3 (hu)
IL (1) IL120718A0 (hu)
MX (1) MX9703032A (hu)
WO (1) WO1997007801A1 (hu)
ZA (1) ZA967223B (hu)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3617976A1 (de) * 1986-05-28 1988-01-14 Alter Sa 1,4-dihydropyridin, verfahren zu dessen herstellung und dessen verwendung in antithrombotischen medikamenten

Also Published As

Publication number Publication date
EA199700053A1 (ru) 1997-12-30
HUP9701695A2 (hu) 1998-03-30
AU6931496A (en) 1997-03-19
CA2203624A1 (en) 1997-03-06
MX9703032A (es) 1997-12-31
KR970706817A (ko) 1997-12-01
JPH10508879A (ja) 1998-09-02
EP0771560A1 (en) 1997-05-07
BR9606691A (pt) 2000-05-09
IL120718A0 (en) 1997-08-14
ZA967223B (en) 1997-03-03
WO1997007801A1 (es) 1997-03-06

Similar Documents

Publication Publication Date Title
PL300235A1 (en) 5-{2-[4-(1,2-benzoisothiazolyl-3)-1-piperozinyl] ethyl}-6-chloro-1,3-dihydro-2h-indolone-2 hydrochloride monohydrate
AU7177296A (en) Crystalline hydrochloride of (R)-(-)-2-N-(4- (1,1-dioxido-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl)- aminomethyl-chroman
SI0807111T1 (en) Substituted heterocyclic compounds, preparation method therefor and pharmaceutical compositions containing same
HUP9900457A3 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
NO970939L (no) Fremgangsmåte ved fremstilling av paroksetinhydrokloridanhydrat
HUP9900947A3 (en) Process for the preparation of piperidine derivatives, intermediates and preparation thereof
AU5578796A (en) Certain substituted benzylamine derivatives: a new class of neuropeptide y1 specific ligands
AU3031797A (en) New substituted 2,4-thiazolidinedione derivatives, processes for producing them and pharmaceutical compositions containing them
PL316382A1 (en) Novel derivatives of piperidine
NZ299788A (en) 4-substituted(4-(1-adamantyl)phenyl) derivatives
IL123171A (en) Process for the preparation of substituted 2-oxazolidinone derivatives and a non-solvated 2-oxazolidinone derivative
GB2304714B (en) New piperidine derivatives, process for obtaining them and pharmaceutical compositions containing them
NO982237D0 (no) Ny fremgangsmÕte for fremstilling av fenylimidazolidinderivater
AU4702496A (en) Oral compositions of h2-antagonists
AU4664596A (en) Antipsychotic 4-(1h-indolyl-1-yl)-1-substituted piperidine derivatives
FR2732217B1 (fr) Forme d'administration solide a usage oral
EE03346B1 (et) Meetod räni sisaldava tulekindla koostise saamiseks
PL310486A1 (en) Novel compounds, derivatives of genistein
PL325687A1 (en) Derivatives of phenyloxymethyl piperidine
NO974155D0 (no) Ny fremgangsmåte for fremstilling av 2,3-dihydrobenzofuranolderivater
HUP9701695A3 (en) Use of 5-ethoxycarbonyl-2,4,6-trimethyl-1,4-dihydropyridine-3-carboxylate of 2-[n-(1,2-benzisothiazolyl-3(2h)one-1,1-dioxide]ethyl for producing pharmaceuticals against atherosclerosis
FR2770433B1 (fr) Dispositif d'usinage de pieces de toutes longueurs a partir de barres
HUP9602637A3 (en) 2-(4-pyrazolyloxy-pyrimidin-5-yl) acetic acid derivatives, producing and using them and fungicid compositions containing them
HUP0004177A3 (en) 4,5-diaryloxazole derivatives, pharmaceutical compositions containing them and process for producing them
FR2757510B1 (fr) Forme microparticulaire d'un derive de tetrahydropyridine